Free tool
FAERS Monitor: Thiola
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019569 or its brand name (Thiola, Tiopronin). Reports on generic versions are filed under their own applications.
Reports
1,772
Serious
332
19% of reports
Hospitalization
213
Death reported
59
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective502
- drug dose omission257
- nausea150
- pain108
- pyrexia83
- rash83
- nephrolithiasis82
- fatigue71
- arthralgia70
- vomiting67
- pruritus64
- diarrhoea58
- headache58
- abdominal discomfort47
- rash generalised42
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 6 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 2 |
| 2010 | 8 |
| 2011 | 36 |
| 2012 | 37 |
| 2013 | 8 |
| 2014 | 3 |
| 2015 | 158 |
| 2016 | 329 |
| 2017 | 592 |
| 2018 | 279 |
| 2019 | 46 |
| 2020 | 21 |
| 2021 | 19 |
| 2022 | 46 |
| 2023 | 28 |
| 2024 | 44 |
| 2025 | 65 |
| 2026 | 32 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,387 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| nephrolithiasisSignal | 82 | 21.3 | 17.2 | 1,563 |
| rash generalisedSignal | 42 | 19.3 | 14.3 | 710 |
| drug dose omissionSignal | 257 | 18.5 | 16.5 | 4,259 |
| drug ineffectiveSignal | 502 | 4.5 | 4.2 | 1,465 |
| abdominal discomfortSignal | 47 | 3.3 | 2.5 | 75 |
| pyrexiaSignal | 83 | 2.8 | 2.3 | 99 |
| rashSignal | 83 | 2.3 | 1.8 | 58 |
| nauseaSignal | 150 | 2.2 | 1.9 | 107 |
| painSignal | 108 | 2.1 | 1.7 | 62 |
| arthralgia | 70 | 2.0 | 1.6 | 35 |
| pruritus | 64 | 2.0 | 1.6 | 30 |
| vomiting | 67 | 1.7 | 1.3 | 19 |
| headache | 58 | 1.1 | 0.9 | 0 |
| fatigue | 71 | 1.1 | 0.9 | 0 |
| diarrhoea | 58 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.